EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy
- Investigator
- Kyle W Ruffing
- Status
- Accepting Candidates
- Ages
- N/A - N/A
- Sexes
- Male